Overview

Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fasting Condition

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open Label, two-treatment, two-period, two-sequence, crossover, single dose pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Quetiapine Fumarate